<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">The effects of LTI-291, an activator of the GCase enzyme and another small molecule therapy, were studied in a 1-month phase 1b trial conducted in the Netherlands, where the frequency of 
 <italic>GBA</italic> mutations was reported to be around 15% [
 <xref ref-type="bibr" rid="CR48">48</xref>]. Around 40 
 <italic>GBA</italic>-PD patients participated. There were no safety events and data showed a good dose-dependent brain penetration (personal communication). The company, Lysosomal Therapeutics, Inc. (LTI), is a Massachusetts-based biotech venture which plans to develop therapies for Gaucher disease and other lysosome-based neurodegenerative diseases.
</p>
